NICE has recommended acalabrutinib-based first-line treatments for mantle cell lymphoma and chronic lymphocytic leukaemia, expanding NHS access following evidence of improved progression-free survival and patient outcomes.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
The UK’s National Institute for Health and Care Excellence (NICE) has recommended two acalabrutinib-based treatment regimens for adults with newly diagnosed mantle cell lymphoma (MCL) and untreated chronic lymphocytic leukaemia (CLL), expanding first-line treatment options for patients with two common B-cell blood cancers. The decisions support the use of acalabrutinib plus bendamustine and rituximab for MCL, and acalabrutinib combined with venetoclax, without obinutuzumab, for previously untreated CLL.
The recommendations are expected to benefit hundreds of patients across England by improving access to targeted therapies that extend disease control while reducing treatment burden compared with conventional approaches.
Expanding First-Line Treatment for Mantle Cell Lymphoma
Mantle cell lymphoma is a rare, aggressive subtype of non-Hodgkin lymphoma that remains incurable with currently available therapies. Many patients present with advanced-stage disease and are not suitable candidates for stem cell transplantation because of age or comorbidities, leaving limited options when the disease relapses.
NICE concluded that adding the Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib to bendamustine and rituximab provides a clinically meaningful improvement over standard chemoimmunotherapy. Clinical evidence showed the combination prolonged median progression-free survival to 72.5 months, compared with 47.8 months for bendamustine and rituximab alone.
Patient representatives told the independent appraisal committee that receiving an incurable diagnosis often causes significant emotional distress. They highlighted the importance of effective first-line treatment in delaying relapse and preserving future therapeutic options.
Oral Targeted Therapy Recommended for Untreated CLL
NICE also recommended acalabrutinib in combination with the BCL-2 inhibitor venetoclax, without obinutuzumab, as a first-line treatment option for adults with untreated chronic lymphocytic leukaemia. Approximately 440 people are expected to benefit from the recommendation.
CLL is the most common form of adult leukaemia in England. Although it generally progresses slowly, the disease can substantially affect physical health, psychological wellbeing, employment, and family life.
The recommendation was supported by evidence from the Phase 3 AMPLIFY trial (NCT03836261), which showed that acalabrutinib plus venetoclax improved both progression-free survival and overall survival compared with standard chemoimmunotherapy.
Unlike intravenous treatment regimens, the combination consists of oral daily tablets, offering a treatment option that may reduce hospital visits and provide greater flexibility for patients. Clinical experts advising NICE also considered the regimen generally well tolerated, making it suitable for a broad range of patients, including older but fit adults.
NICE Highlights Clinical and Quality-of-Life Benefits
Helen Knight, Director of Medicines Evaluation at NICE, said both blood cancers have a profound physical and psychological impact on patients and their families.
She noted that people frequently describe the anxiety associated with waiting to see whether treatment will work and worrying about disease progression. According to Knight, the new recommendations provide additional treatment choices that can delay disease progression while fitting more easily into everyday life through oral administration and fewer hospital visits.
Patient Perspective Reinforces Need for Better Options
Ruth Lester, a patient representative from Lymphoma Action who has lived with mantle cell lymphoma for 13 years, welcomed the recommendation.
Diagnosed after experiencing unexplained infections for 18 months, Lester initially underwent active monitoring before receiving bendamustine and rituximab followed by maintenance therapy after deciding against stem cell transplantation. Despite treatment-related immune and lung complications, she continues to live independently and remains active as a charity trustee and pianist.
She said the availability of a better tolerated first-line treatment offers hope that more people with MCL will experience longer periods of disease control while maintaining quality of life.
Regulatory Status
The recommendations support broader adoption of acalabrutinib-based targeted therapy within the National Health Service for newly diagnosed MCL and untreated CLL. NICE’s evaluations were conducted under guidance in development GID-TA11091 for mantle cell lymphoma and GID-TA11230 for chronic lymphocytic leukaemia. Once final guidance is published, eligible patients across England are expected to gain routine access to both treatment options through the NHS.
Reference
About the Writer
Farha Farheen, PharmD (LinkedIn) is a pharmacy professional with a strong interest in pharmacovigilance and clinical research. She has completed her Doctor of Pharmacy (Pharm.D) along with her internship as a Clinical Pharmacist. She has hands-on experience in adverse drug reaction (ADR) reporting, safety data documentation, and pharmacovigilance workflows, and is proficient in using VigiFlow. She is also a patent holder for an antibacterial formulation enriched with bioactive substances, granted by the German Patent and Trademark Office.